Answer
The UK licence requires an activating ESR1 mutation, so a validated plasma test is used to identify patients whose cancer meets this criterion.
Sources for this answer
- Korserdu (elacestrant) 86mg film-coated tabletsemc · SmPC Current selected SmPC · Version 3